FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGE	S IN BENEFICIA	L OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response.	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					_		. ,				ilpaily Act	00.0								
	nd Address of CH KEV	Reporting Person*					r Name <b>an</b> a Pharn								lationship o ck all applica Director	able)	g Perso	on(s) to Issu 10% Ov		
	,	<del></del>												\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	Officer	give title		Other (s	·	
(Last) (First) (Middle)					3. [	Date of Earliest Transaction (Month/Day/Year)								- $X$	below)			below)	` '	
C/O ATHIRA PHARMA, INC.					01/19/2023								Executive VP, Research							
			SHITE 10.	1																
18706 NORTH CREEK PARKWAY, SUITE 104				<u> </u>	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Inc	6. Individual or Joint/Group Filing (Check Applicable					
(Street)						(									Line)					
BOTHE	LL W	'A	98011											X		•	•	rting Persor	I	
														Form filed by More than One Reporting Person				ting		
(City)	(S	tate)	(Zip)																	
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
Date			Date	Date Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year		Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4		A) or 3, 4 and 5)	5. Amour Securitie Beneficia Owned F Reported	s Illy ollowing	Form (D) or	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
								Code	v	Amount (A) (C)		or	Price	Transacti (Instr. 3 a	ion(s)			,iii3ti. 4)		
Common Stock <sup>(1)</sup>			11/18/	8/2022(2)				A	V	657 A		\$2.74(3)	62,052			D				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Yea	Code (I			Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title a of Secu Underly Derivati (Instr. 3	rities ing ve Se	curity	8. Price of Derivative Security (Instr. 5)		e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
						v	(A)					Amor		mount		(Instr. 4)	UII(3)			
				Co	ode				Date Exercisab		xpiration ate	Title	N	umber Shares						
Stock Option (Right to Buy)	\$3.37	01/19/2023		A			150,000		(4)	0	1/18/2033	Common Stock 150		50,000	\$0.00	150,000		D		

## Explanation of Responses:

- 1. The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of May 18, 2022 through November 18, 2022. This transaction is also exempt under Rule 16b-3(c).
- 2. The Purchase Period ended November 18, 2022 and is the sole Purchase Period in the Offering Period (as defined in the ESPP) that began May 18, 2022.
- 3. In accordance with the ESPP, these shares were purchased based on 85% of the closing price on November 18, 2022.
- 4. One thirty-sixth (1/36th) of the shares subject to the option will vest on February 19, 2023 and one thirty-sixth of the shares subject to the option will vest each month thereafter.

## Remarks:

/s/ Glenna Mileson, Attorneyin-Fact for Kevin Church

01/23/2023

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.